1. Immunology/Inflammation
  2. Thrombopoietin Receptor

Thrombopoietin Receptor

Thrombopoietin (TPO) is the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

TPO binds to the thrombopoietin receptor (TPOr, also termed c-mpl) on platelets, megakaryocytes, and pluripotent stem cells leading to inhibition of apoptosis of stem cells and megakaryocytes; increased megakaryocyte number, size, and ploidy; increased rate of megakaryocyte maturation and platelet count; and decreased platelet threshold for activation by ADP and collagen.

Thrombopoietin Receptor 相关产品 (5):

Cat. No. Product Name Effect Purity
  • HY-15306
    Eltrombopag Agonist 99.61%
    Eltrombopag(SB-497115)是口服活性的促血小板生成素受体激动剂,能刺激血小板生成。
  • HY-15306A
    Eltrombopag Olamine Agonist >98.0%
    Eltrombopag乙醇胺是口服活性的促血小板生成素受体激动剂。
  • HY-13463
    Avatrombopag Agonist
    Avatrombopag(AKR-501;AS1670542)是血小板生成素受体(TPO受体)的新型具口服活性激动剂,EC50值为3.3nM。
  • HY-100380
    TPO agonist 1 Agonist >98.0%
    TPO 受体激动剂能够通过刺激TPO受体增加血小板的产生。
  • HY-19883
    Lusutrombopag Agonist 98.81%
    Lusutrombopag 是一种可口服的血小板生成素受体 (thrombopoietin receptor) 激动剂,用于治疗慢性肝病。